P575: AZA-related toxicity isn't aggravated by concomitant drugs in IBD patientsECCO '17 Barcelona
2017
P576: Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn's disease?ECCO '17 Barcelona
2017
P577: “Treat to target” recommendations in ulcerative colitis in practice: clinician perceptions and potential barriersECCO '17 Barcelona
2017
P578: Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort studyECCO '17 Barcelona
2017
P579: Complete disease resolution after allogenic hematopoietic stem cell transplantation in children with very early onset inflammatory disease and no identified monogenic mutationECCO '17 Barcelona
2017
P580: Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's disease – a multicenter “real life” studyECCO '17 Barcelona
2017
P582: The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016ECCO '17 Barcelona
2017
P583: Trends in endoscopy management after surgery in a national cohort of Spanish Crohn's disease patients. Results from PRACTICROHN studyECCO '17 Barcelona
2017
P584: A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?ECCO '17 Barcelona
2017
P585: Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategyECCO '17 Barcelona
2017
P586: A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experienceECCO '17 Barcelona
2017
P587: Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controlsECCO '17 Barcelona
2017
P588: Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54ECCO '17 Barcelona
2017
P589: Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysisECCO '17 Barcelona
2017
P590: Reasons for discontinuation and switch of biologic therapy in IBD: findings from a large international observational study (03)ECCO '17 Barcelona
2017
P591: Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approachECCO '17 Barcelona
2017
P592: Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohortECCO '17 Barcelona
2017